Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: US FDA Enters Year's Final Stretch With Tsunami Of Novel Approvals

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.
Advertisement

Related Content

Vitrakvi, Daurismo Approvals Put US FDA On Brink Of Another Record
Keeping Track: Yupelri Is Latest Novel Drug Approved, But Bad News For Biosimilars
Keeping Track: FDA Starts November With A Bang
US FDA Blows Past Novel Approvals Record On Way To Unprecedented Year For New Drugs
Celltrion’s Rituximab Biosimilar Has Easy US FDA Panel Ride Despite Questions About Narrow Label
Celltrion’s Biosimilar Rituximab Brings Indication Carve Outs To US FDA Panel Review
Keeping Track: US FDA Approvals For Tibsovo, Kisqali And Second Neupogen Biosimilar
Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission
Breakthrough No Guarantee Of Success
Catalyst Stumbles With Filing Of Controversial 'Breakthrough Therapy' Firdapse

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel